Skip to main content
. 2024 May 31;25(11):6082. doi: 10.3390/ijms25116082

Figure 1.

Figure 1

The expression of serum miRNAs is associated with the survival of patients with ESCC treated with radiotherapy. (A) Schematic diagram of the study workflow. (B–I) The relative expression levels of miR-143-3p, miR-181a-5p, miR-223-3p, and miR-337-3p at baseline and during radiotherapy in the progression-free group (B–E) and the progression group (F–I), respectively. (J,K) The prediction accuracy for radiotherapy based on the fold change in a single miRNA (J) or double miRNAs (K). (L,M) The overall survival (OS, L) and progression-free survival (PFS, M) of patients in the radiation-sensitive group (both ≤ 1.5-fold) and resistant group (any > 1.5-fold) predicted using miR-143-3p and miR-223-3p. (N,O) The ROC curve of KPS, primary lesion volume, and the fold change in miR-143-3p and miR-223-3p in predicting OS (N) and PFS (O). Abbreviations: miRNA, microRNA; ESCC, esophageal squamous cell carcinoma; ROC, receiver operating characteristic; KPS, Karnofsky Performance Status; BGISEQ-500, Beijing Genomics Institute high-throughput sequencing; miRNA-Seq, microRNA sequencing; TPM, Transcripts Per Kilobase Million.